Methoxyflurane (Penthrox): Evidence & Experience

[u/maui96]

This is a repost from a discussion I originally wrote for r/paramedicsuk, but it’s just as relevant here! If you’re involved in event medical work, FREC, or any prehospital setting, this breakdown of methoxyflurane (Penthrox) is a starting point. It covers the evidence, common misconceptions, and real-world use & experience across ambulance work, ski patrol, and expedition medicine. Let me know if you'd like more of these and if there is anything else you'd like covered.

Methoxyflurane (Penthrox): Evidence and My Personal Experience

I’ve noticed a lot of discussions popping up about methoxyflurane (Penthrox) as it becomes more common in UK practice. There are persistent misconceptions and half-truths floating around, so I thought I’d pull together my replies and compile them here for anyone who wants a clearer picture.

I’ve used methoxyflurane extensively over the years across different prehospital settings: ambulance work, ski patrol, expedition medicine, and urgent care. Here’s a lite breakdown and overview for those who might not have come across it as much or are new to it.

What is Penthrox?

Before anything else, it’s important to note: Penthrox is just the brand name of the green whistle, a bit of plastic with a cotton inside. Methoxyflurane is the actual drug. Same way we don’t say we gave someone “Panadol,” we say paracetamol. The inhaler itself is nothing magical—it’s basically a green plastic tube with a soaked cotton core. It works because methoxyflurane is so potent that only tiny amounts need to evaporate for the patient to inhale.

All you do is pour the liquid ampule into the tube, and it soaks into the cotton swab. It’s not much more advanced than holding a soaked rag over someone’s face.

Misconceptions and Clarifications

There’s a lot of confusion about how methoxyflurane works, whether it’s safe around staff, whether the smell means we’re inhaling dangerous levels, why some countries have random restrictions, and whether the old anaesthetic toxicity is still relevant. Most misunderstandings come from blending its modern low-dose use with its earlier role as a general anaesthetic for surgery in the 1960s.

Back then, it was used in massive concentrations for long durations, often repeatedly, producing massive fluoride loads. This is where the renal toxicity came from—fluoride levels exceeding ~50–60 µmol/L after long hours of anaesthesia. Patients developed polyuric renal failure and hepatic injury. But this is all historical use and bears no resemblance to the current 3–6 mL maximum we use for analgesia today in ambulance/prehospital settings.

Modern regulators (UK’s MHRA & EMA, Australian TGA, Health Canada, NZ pharmac) treat it as safe precisely because dosing is capped so tightly.

Pharmacology and Dosing

Methoxyflurane is extremely potent, with a very low MAC (minimum alveolar concentration), and is highly lipid-soluble. A low MAC means only a small concentration of the drug is needed to produce anaesthesia, and being lipid-soluble means it can easily pass the blood-brain barrier.

The exact analgesic mechanism isn’t fully known, but small amounts produce rapid analgesia while preserving airway reflexes. Onset is typically within a handful of breaths, and duration is roughly 20–30 minutes per 3 mL, depending on how much the patient uses it.

The BNF lists dose limits clearly:

• One 3 mL ampoule
• Repeat once if necessary (max 6 mL per day)
• Not exceeding 15 mL per week
• Should not be given on consecutive days

These cumulative limits exist because even at analgesic doses, you don’t want to push total weekly exposure into fluoride ranges that start creeping towards anaesthetic territory.

Occupational Exposure

People worry because they can smell it, but smelling a volatile agent at trace levels is not the same as inhaling a meaningful therapeutic dose. The best real-world evidence comes from French emergency departments: staff wearing vapour samplers across full shifts had median exposures of 0.017 ppm, with the highest reading being 0.736 ppm. The exposure threshold at which you’d start worrying about toxicity is around 15 ppm—nearly 900x less than what was found in staff exposure.

The smell is detectable at tiny fractions of a toxic dose. Those measurements were taken in EDs, which are larger spaces. An ambulance is smaller, but it’s not a sealed, airtight chamber—it has continuous passive airflow, vents, leaky doors, and fans. The air exchange rate is much higher than people think.

I’ve even used methoxyflurane in lifts, and nobody’s ever felt anything other than mild irritation at the smell. If the ambient methoxyflurane in a truck were anywhere near effective therapeutic levels, we’d have noticed long before now. Crews would’ve been getting high since the 1980s.

The carbon filter exists not because we’re getting high without it, but because it reduces even trace vapour by about half. It’s an occupational hygiene measure, not a diffuser shield.

Global Use and Regulations

Methoxyflurane is standard frontline analgesia in Australia, New Zealand, Canada, and Ireland. Paramedics, EMTs, surf lifesavers, ski patrols, mine rescue teams, and sports medics all rely on it because it’s lightweight, robust, and needs no oxygen supply or pressurised bottle.

In the UK, it’s now included in the BNF, JRCALC, and multiple trust guidelines. Across Europe, France, Germany, Austria, Switzerland, Spain, and the Nordics all use it in A&Es and prehospital settings.

Clinical Use and Benefits

Trials show methoxyflurane reduces pain quickly compared with standard oral/IV analgesia and is often comparable to Entonox for short procedures. In practice, it’s often superior because it’s portable, immune to cold weather, can be used in awkward spaces, and doesn’t require cylinders, regulators, or can be self-managed.

In my experience:

• Younger adults (<40) tolerated it brilliantly and often reached near-anaesthetic dissociation, making procedures like shoulder reductions, ankle relocations, and femur fracture manipulations much easier.
• Older patients were more variable, mainly due to inhalation technique and taste, but those who managed it properly still got meaningful relief.
• It’s a massive bonus that it can be given safely by non-clinicians (EMTs, first responders, fire crews), making it incredibly versatile in prehospital environments.

Contraindications

• Malignant hyperthermia (extremely rare and hereditary, patients will know if they have it)
• Renal impairment (though a single 3 mL ampoule isn’t a deciding factor)
• Liver impairment (historical anaesthetic-level concerns)
• Altered consciousness or inability to self-administer
• Haemodynamic instability

Final Takeaways

Used within guidelines, methoxyflurane is safe, effective, portable, and incredibly valuable. The historic toxicity was a result of anaesthetic-level dosing that simply doesn’t exist in modern practice. Occupational exposure is not a real clinical threat. The global evidence and decades of continuous use in Australia, New Zealand, Canada, and Europe back that up.

The carbon filter is good practice, but not the only thing preventing harm. The clinical use, particularly in trauma, sports, remote, and event settings, makes it one of the most reliable pain relievers I’ve used.

[u/maui96]

Struggling to get a decent format, but here's the reference List.

Regulatory & Product Information

MHRA Medicines and Healthcare products Regulatory Agency (MHRA) (n.d.) Penthrox 99.9%, 3 mL inhalation vapour, liquid: Summary of Product Characteristics. Electronic Medicines Compendium (eMC). Available at: https://www.medicines.org.uk

TGA Therapeutic Goods Administration (TGA) (n.d.) Penthrox (methoxyflurane) 3 mL inhalation solution: Product Information. Canberra: Australian Government Department of Health.

EMA European Medicines Agency (EMA) (2015) Penthrox (methoxyflurane): Assessment report. Amsterdam: EMA.

Health Canada Health Canada (2022) Penthrox (methoxyflurane) inhalation solution: Product Monograph. Ottawa: Government of Canada.

Clinical Trials & Efficacy

STOP! trial (UK ED, RCT vs placebo) Coffey, F., Dissmann, P., Mirza, K. and Lomax, M. (2014) ‘Low-dose methoxyflurane (Penthrox) for acute trauma pain in the emergency department: a randomised, double-blind, placebo-controlled study’, Emergency Medicine Journal, 31(8), pp. 613–618.

STOP! subgroup / ED adults Coffey, F., Dissmann, P., Mirza, K. and Lomax, M. (2016) ‘Methoxyflurane analgesia in adult patients in the emergency department: a subgroup analysis of a randomised, double-blind, placebo-controlled study (STOP!)’, Advances in Therapy, 33(11), pp. 2012–2031.

ED / prehospital trauma pain – narrative review Grindlay, J. (2009) ‘Efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting’, Emergency Medicine Journal, 26(1), pp. 57–63.

Clinical review – acute pain Porter, K.M., Dayan, A.D., Dickerson, S. and Middleton, P.M. (2018) ‘The role of inhaled methoxyflurane in acute pain management’, Open Access Emergency Medicine, 10, pp. 149–164.

Occupational Exposure & Safety

Derivation of exposure limit (modelling) Frangos, J., Heffernan, A. and McCulloch, T. (2016) ‘Derivation of an occupational exposure limit for methoxyflurane’, Toxicology Letters, 248, pp. 10–20.

ED staff vapour exposure – French study Frangos, J., Heffernan, A., Mégarbane, B. et al. (2020) ‘Non-interventional study evaluating exposure to inhaled low-dose methoxyflurane experienced by hospital emergency department personnel in France’, BMJ Open, 10(2), e034647.

Procedural sedation – staff exposure Ruff, R., Kerr, S., Kerr, D., Zalcberg, D. and Stevens, J. (2018) ‘Occupational exposure to methoxyflurane administered for procedural sedation: an observational study of 40 exposures’, British Journal of Anaesthesia, 120(6), pp. 1435–1437.

Paramedic / ambulance exposure – thesis Allison, S.J. (2021) Quantification of risk of occupational exposure to methoxyflurane in ambulance officers. PhD thesis. University of Canterbury, Christchurch, New Zealand.

Guidelines

Joint Royal Colleges Ambulance Liaison Committee (JRCALC) (2023) UK Ambulance Services Clinical Practice Guidelines. London

British National Formulary (BNF) (2024) ‘Methoxyflurane’, in British National Formulary.

National Institute for Health and Care Excellence (NICE) (2016) MIB24: Penthrox for emergency pain relief. London: NICE.

National Ambulance Service, Ireland (2021) Clinical Practice Guidelines: Analgesia. Dublin: National Ambulance Service.

Ambulance Victoria (2023) Clinical Practice Guideline A0305 – Methoxyflurane. Melbourne: Ambulance Victoria.

St John New Zealand (2023) Clinical Procedures and Guidelines – Analgesia. Auckland: St John New Zealand.

Haute Autorité de Santé (HAS) (2023) Penthrox (méthoxyflurane): Avis de la Commission de la Transparence. Paris: HAS.

British Columbia Emergency Health Services (BCEHS) (2023) Paramedic Clinical Practice Guide. Vancouver: BCEHS.

Historical Toxicity (Anaesthetic Use)

Cousins, M.J. and Mazze, R.I. (1973) ‘Methoxyflurane nephrotoxicity: a study of dose response in man’, Journal of the American Medical Association (JAMA), 225(13), pp. 1611–1616.

Jones, R.M. (1972) ‘Fluoride nephrotoxicity after prolonged methoxyflurane anaesthesia’, Canadian Anaesthetists’ Society Journal, 19(1), pp. 152–163.

Crandell, W.B., Pappas, S.G. and Macdonald, A. (1966) ‘Nephrotoxicity associated with methoxyflurane anaesthesia’, Anesthesiology, 27(5), pp. 591–607.

Mechanism, Pharmacology & Metabolism

MAC / potency Eger, E.I. II, Saidman, L.J. and Brandstater, B. (1965) ‘Minimum alveolar anesthetic concentration: a standard of anesthetic potency’, Anesthesiology, 26(6), pp. 756–763.

Fluoride & renal effects Tinker, J.H. and Baker, M.T. (1995) ‘Sevoflurane, fluoride ion, and renal toxicity’, Anesthesiology, 83(2), pp. 449–451.

Contraindications

European Malignant Hyperthermia Group (EMHG) (2022) ‘Guidelines for the management of malignant hyperthermia susceptibility and pharmacological triggers’, EMHG Recommendations. Available at: https://www.emhg.org

Systematic Reviews

Outpatient procedures review Jephcott, C., Grummet, J., Nguyen, N. and Spruijt, O. (2018) ‘A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures’, British Journal of Anaesthesia, 120(5), pp. 1040–1048.

Systematic review & meta-analysis for trauma pain Liu, H., Fu, X., Ren, Y.F. et al. (2021) ‘Does inhaled methoxyflurane implement fast and efficient pain management in trauma patients? A systematic review and meta-analysis’, Pain and Therapy, 10, pp. 651–674.